Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 12/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15733045 | 0.90 | PTPN1 (0.54) | PTPN1SOAT1PKMS100A4MEN1 | |
| SCHEMBL15732842 | 0.88 | PTPN1 (0.60) | PTPN1SOAT1PKMS100A4 | |
| SCHEMBL15732985 | 0.87 | PTPN1 (0.63) | PTPN1SOAT1S100A4 | |
| SCHEMBL15733081 | 0.87 | PTPN1 (0.63) | PTPN1SOAT1S100A4 | |
| SCHEMBL15732974 | 0.87 | PTPN1 (0.63) | PTPN1SOAT1S100A4 | |
| SCHEMBL15732933 | 0.87 | PTPN1 (0.63) | PTPN1SOAT1S100A4 | |
| SCHEMBL15732809 | 0.87 | PTPN1 (0.63) | PTPN1SOAT1S100A4 | |
| SCHEMBL15732904 | 0.85 | SOAT1 (0.43) | PTPN1SOAT1PKMS100A4MEN1 | |
| SCHEMBL1137898 | 0.81 | PTPN1 (0.56) | PTPN1SOAT1PKMS100A4MEN1 | |
| SCHEMBL4848431 | 0.75 | PTPN1 (0.69) | PTPN1SOAT1S100A4ALDH1A1PARK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | ONO PHARMACEUTICAL CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| EP-0659883-B1 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6432913-B1 | ANTIDIABETIC AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6303320-B1 | SCREENING FOR MODULATOR OF GLUCOSE USE; ADMINISTER MODULATOR TO CELLS IN VITRO, CULTURE CELLS, COMPARE PHOSPHORYLATED PROTEIN WITH GLUCOSE USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-5804411-A | KEY PROTEIN IN THE SIGNAL TRANSMISSION OF INSULIN; USEFUL IN THE PREVENTION AND/OR TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5506205-A | TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0659883-A2 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | IAPP, FAM20C, GID4 | PTPN1 246/4885SOAT1 1909/4885PKM 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.